Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

ASH 2017

9 - 12 Dec 2017
Georgia World Congress Center, Atlanta, United States of America
Videos
News
Next generation sequencing identifies smoldering multiple myeloma patients with...
Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA
Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression ( Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA )
14 Dec 2017
Venetoclax plus rituximab for patients with relapsed / refractory CLL
Prof John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
Venetoclax plus rituximab for patients with relapsed / refractory CLL ( Prof John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )
12 Dec 2017
Daratumumab for patients with multiple myeloma
Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain
Daratumumab for patients with multiple myeloma ( Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain )
12 Dec 2017
Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib...
Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...
Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone for multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )
12 Dec 2017
Multiple myeloma analysis from ASH 2017
Dr Maxim Solovev and Dr Sung-Soo Yoon
Multiple myeloma analysis from ASH 2017 ( Dr Maxim Solovev and Dr Sung-Soo Yoon )
12 Dec 2017
Multiple myeloma highlights from ASH 2017
Prof Meral Beksac - Ankara University Medical School, Ankara, Turkey
Multiple myeloma highlights from ASH 2017 ( Prof Meral Beksac - Ankara University Medical School, Ankara, Turkey )
12 Dec 2017
ASH 2017: Immunotherapy for multiple myeloma
Prof Paul Richardson & Dr Wenming Chen
ASH 2017: Immunotherapy for multiple myeloma ( Prof Paul Richardson & Dr Wenming Chen )
12 Dec 2017
Edoxaban versus dalteparin for venous thromboembolism associated with cancer
Dr Harry Büller - University of Amsterdam, Amsterdam, Netherlands
Edoxaban versus dalteparin for venous thromboembolism associated with cancer ( Dr Harry Büller - University of Amsterdam, Amsterdam, Netherlands )
12 Dec 2017
Lenalidomide with rituximab for mantle cell lymphoma
Prof Jia Ruan - Weill Cornell Medicine and New York Presbyterian Hospital, New...
Lenalidomide with rituximab for mantle cell lymphoma ( Prof Jia Ruan - Weill Cornell Medicine and New York Presbyterian Hospital, New York, USA )
11 Dec 2017
Combination chemotherapy for multiple myeloma
Dr Muzaffar Qazilbash - MD Anderson Cancer Center, Houston, USA
Combination chemotherapy for multiple myeloma ( Dr Muzaffar Qazilbash - MD Anderson Cancer Center, Houston, USA )
11 Dec 2017
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and...
Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )
11 Dec 2017
Gilteritinib combination with induction and consolidation chemo in newly...
Dr Keith Pratz - Johns Hopkins University, Baltimore, USA
Gilteritinib combination with induction and consolidation chemo in newly diagnosed AML ( Dr Keith Pratz - Johns Hopkins University, Baltimore, USA )
11 Dec 2017
REGN2810 alone or in combination with REGN1979 for B-lymphoid malignancies
Dr Max Topp - University of Wurzburg, Wurzburg, Germany
REGN2810 alone or in combination with REGN1979 for B-lymphoid malignancies ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )
11 Dec 2017
Results of the AML 12 trial
Dr Ana Garrido - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Results of the AML 12 trial ( Dr Ana Garrido - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )
11 Dec 2017
Added ibrutinib in first-line CLL treatment
Dr Nitin Jain - MD Anderson Cancer Center, Houston, USA
Added ibrutinib in first-line CLL treatment ( Dr Nitin Jain - MD Anderson Cancer Center, Houston, USA )
11 Dec 2017
T cell therapy for ALL
Dr Max Topp - University of Wurzburg, Wurzburg, Germany
T cell therapy for ALL ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )
11 Dec 2017
Immunosuppressive therapy in myelodysplastic syndrome
Dr Maximilian Stahl - Yale Cancer Center, New Haven, USA
Immunosuppressive therapy in myelodysplastic syndrome ( Dr Maximilian Stahl - Yale Cancer Center, New Haven, USA )
11 Dec 2017
The ACE-LY-004 study of acalabrutinib monotherapy for mantle cell lymphoma
Dr Michael Wang - MD Anderson Cancer Center, Houston, USA
The ACE-LY-004 study of acalabrutinib monotherapy for mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )
11 Dec 2017
Hypomethylating agents for relapsed and refractory acute myeloid leukaemia
Dr Maximilian Stahl - Yale Cancer Center, New Haven, USA
Hypomethylating agents for relapsed and refractory acute myeloid leukaemia ( Dr Maximilian Stahl - Yale Cancer Center, New Haven, USA )
11 Dec 2017
Epidemiology data for acute myeloid leukaemia and the ALESE study
Dr James Foran - Mayo Clinic Florida, Jacksonville, USA
Epidemiology data for acute myeloid leukaemia and the ALESE study ( Dr James Foran - Mayo Clinic Florida, Jacksonville, USA )
10 Dec 2017
Combination of steroids with ponatinib as frontline therapy for acute...
Dr Giovanni Martinelli - University of Bologna, Bologna, Italy
Combination of steroids with ponatinib as frontline therapy for acute lymphoblastic leukaemia ( Dr Giovanni Martinelli - University of Bologna, Bologna, Italy )
10 Dec 2017
Shortening the time to manufacture CAR T-cells
Dr Partow Kebriaei - MD Anderson Center, Houston, USA
Shortening the time to manufacture CAR T-cells ( Dr Partow Kebriaei - MD Anderson Center, Houston, USA )
10 Dec 2017
ASPIRE update: Carfilzomib triplet for relapsed / refractory myeloma
Prof Keith Stewart - Mayo Clinic, Scottsdale, USA
ASPIRE update: Carfilzomib triplet for relapsed / refractory myeloma ( Prof Keith Stewart - Mayo Clinic, Scottsdale, USA )
10 Dec 2017
Early platelet drop in myelodysplastic syndrome highlights prognostic classifier
Dr Raphael Itzykson - Hopital Saint-Louis, Paris Diderot University, Paris...
Early platelet drop in myelodysplastic syndrome highlights prognostic classifier ( Dr Raphael Itzykson - Hopital Saint-Louis, Paris Diderot University, Paris, France )
10 Dec 2017
Six-month follow up of CTL019 for diffuse large B-cell lymphoma
Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA
Six-month follow up of CTL019 for diffuse large B-cell lymphoma ( Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA )
10 Dec 2017
New treatment strategies for multiple myeloma
Dr James Kochenderfer - National Cancer Institute, Bethesda, USA
New treatment strategies for multiple myeloma ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )
10 Dec 2017
Anti-BCMA CAR T cell therapy for multiple myeloma
Dr James Kochenderfer - National Cancer Institute, Bethesda, USA
Anti-BCMA CAR T cell therapy for multiple myeloma ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )
10 Dec 2017
Axicabtagene ciloleucel for patients with non-hodgkin lymphoma
Dr Sattva Neelapu - MD Anderson Cancer Center, Houston, USA
Axicabtagene ciloleucel for patients with non-hodgkin lymphoma ( Dr Sattva Neelapu - MD Anderson Cancer Center, Houston, USA )
10 Dec 2017
Data from the CLARITY trial of ibrutinib plus venetoclax
Prof Peter Hillmen - University of Leeds, Leeds, UK
Data from the CLARITY trial of ibrutinib plus venetoclax ( Prof Peter Hillmen - University of Leeds, Leeds, UK )
10 Dec 2017
Mogamulizumab for cutaneous T- cell lymphoma
Prof Youn Kim - Stanford University, Stanford, CA
Mogamulizumab for cutaneous T- cell lymphoma ( Prof Youn Kim - Stanford University, Stanford, CA )
10 Dec 2017
Phase 1 study of Blu-285 in advanced systemic mastocytosis
Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA
Phase 1 study of Blu-285 in advanced systemic mastocytosis ( Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA )
10 Dec 2017
Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial
Prof Peter Hillmen - University of Leeds, Leeds, UK
Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial ( Prof Peter Hillmen - University of Leeds, Leeds, UK )
10 Dec 2017
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B...
Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA
Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma ( Dr Stephen Schuster - University of Pennsylvania, Philadelphia, USA )
10 Dec 2017
Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study
Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada
Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study ( Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada )
10 Dec 2017
New treatments for acute myeloid leukaemia
Dr Anna Halpern - Seattle Cancer Care Alliance, Seattle, USA
New treatments for acute myeloid leukaemia ( Dr Anna Halpern - Seattle Cancer Care Alliance, Seattle, USA )
10 Dec 2017
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's...
Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma ( Dr Joseph Connors - British Columbia Cancer Agency, Vancouver, Canada )
10 Dec 2017
Long term follow up on the ZUMA-1 trial for nHL
Dr Sattva Neelapu - MD Anderson Center, Houston, USA
Long term follow up on the ZUMA-1 trial for nHL ( Dr Sattva Neelapu - MD Anderson Center, Houston, USA )
10 Dec 2017
BLU-285 for advanced systemic mastocytosis
Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA
BLU-285 for advanced systemic mastocytosis ( Prof Daniel DeAngelo - Dana-Farber Cancer Institute, Boston, USA )
10 Dec 2017
Mogamulizumab demonstrates significant improvement in progression free survival...
Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA
Mogamulizumab demonstrates significant improvement in progression free survival for CTCL ( Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Dec 2017
Autoimmune and infectious diseases among diffuse large B-cell lymphoma survivors
Dr Tanaya Shree - Stanford University Medical Center, Stanford, USA
Autoimmune and infectious diseases among diffuse large B-cell lymphoma survivors ( Dr Tanaya Shree - Stanford University Medical Center, Stanford, USA )
9 Dec 2017
Autologous haematopoietic cell transplant for mantle cell lymphoma
Dr Stefan Barta - Fox Chase Cancer Center, Philadelphia, USA
Autologous haematopoietic cell transplant for mantle cell lymphoma ( Dr Stefan Barta - Fox Chase Cancer Center, Philadelphia, USA )
9 Dec 2017
Dexamethasone and the UKALL 2011 trial
Dr John Moppett - University Hospitals Bristol NHS Foundation Trust, Bristol, UK
Dexamethasone and the UKALL 2011 trial ( Dr John Moppett - University Hospitals Bristol NHS Foundation Trust, Bristol, UK )
9 Dec 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation